Dichlororibofuranosylbenzimidazole

Publication Title: 
Cell Death and Differentiation

Terminally differentiated neutrophils are short-lived but the key effector cells of the innate immune response, and have a prominent role in the pathogenesis and propagation of many inflammatory diseases. Delayed apoptosis, which is responsible for their extended longevity, is critically dependent on a balance of intracellular survival versus pro-apoptotic proteins. Here, we elucidate the mechanism by which the cyclin-dependent kinase (CDK) inhibitor drugs such as R-roscovitine and DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) mediate neutrophil apoptosis.

Author(s): 
Leitch, A. E.
Lucas, C. D.
Marwick, J. A.
Duffin, R.
Haslett, C.
Rossi, A. G.
Publication Title: 
The Journal of Pharmacology and Experimental Therapeutics

Clinically used calcineurin inhibitors, including tacrolimus (FK506) and cyclosporine A, can induce calcineurin inhibitor-induced pain syndrome (CIPS), which is characterized as severe pain and pain hypersensitivity. Increased synaptic N-methyl-D-aspartate receptor (NMDAR) activity in the spinal dorsal horn plays a critical role in the development of CIPS. Casein kinase II (CK2), a serine/threonine protein kinase, can regulate synaptic NMDAR activity in the brain.

Author(s): 
Hu, Yi-Min
Chen, Shao-Rui
Chen, Hong
Pan, Hui-lin
Subscribe to RSS - Dichlororibofuranosylbenzimidazole